[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508545":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":56,"collaborators":19,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":19,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":19,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous induced neural stem cell-derived DA precursor cells","EXPERIMENTAL","The patients will receive transplantation of autologous induced neural stem cell-derived DA precursor cells.",[13],"Drug: Autologous induced neural stem cell-derived DA precursor cells",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Zhiguo Chen, Ph.D.","CONTACT","+86-10-83198889","chenzhiguo@gmail.com",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Jinghong Ma, M.D.","+86-10-83198677","jinghongma@163.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Xuanwu Hospital Capital Medical University","RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46,48,50,52,54],{"name":22,"role":23,"phone":47,"phoneExt":19,"email":25},"86-10-83198889",{"name":22,"role":49,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"name":51,"role":49,"phone":19,"phoneExt":19,"email":19},"Biao Chen, M.D., Ph.D.",{"name":53,"role":49,"phone":19,"phoneExt":19,"email":19},"Guoguang Zhao, M.D., Ph.D.",{"name":55,"role":49,"phone":19,"phoneExt":19,"email":19},"Jie Lu, M.D., Ph.D.",{"type":57,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100508545","phase-1-safety-and-efficacy-of-autologous-insc-dap-in-the-treatment-of-parkinsons-disease-100508545",false,"NCT05901818","Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease","Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease","Inclusion Criteria:\n\nAges between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication \"on\" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).\n\nExclusion Criteria:\n\nAtypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\\\u003C24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1\u002F4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators\u002Fphysicians.","ALL","30 Years","85 Years",{"count":69,"type":70},6,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.",[76],"Parkinson's Disease",[78],"Autologous; iNSC; DA precursor cells; Parkinson's Disease; Cell therapy; Stereotaxic injection","2026-06-29",{"date":81,"type":82},"2026-07-01","ACTUAL",{"date":84,"type":82},"2021-04-01",{"date":86,"type":70},"2028-12-31",{"name":5,"class":6},1]